Titan Pharmaceuticals Inc (TTNP)

4.20
0.05 1.18
NASDAQ : Health Care
Prev Close 4.25
Open 4.20
Day Low/High 4.20 / 4.35
52 Wk Low/High 2.57 / 10.00
Volume 78.95K
Avg Volume 133.80K
Exchange NASDAQ
Shares Outstanding 21.20M
Market Cap 90.10M
EPS 0.70
P/E Ratio 7.33
Div & Yield N.A. (N.A)

Latest News

TTNP: Insiders vs. Shorts

TTNP: Insiders vs. Shorts

The most recent short interest data was recently released for the 10/14/2016 settlement date, and Titan Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 12.68 "days to cover" versus the median component at 6.24. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Analysts' Actions -- American Eagle, Mattel, Netflix, Tesaro and More

Analysts' Actions -- American Eagle, Mattel, Netflix, Tesaro and More

Here are Monday's top research calls, including upgrades for American Eagle, Mattel and Tesaro, and new coverage of Netflix.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CVRR, TTNP, WMS Downgrades: DAR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Noteworthy Wednesday Option Activity: TTNP, FCEL, PRLB

Noteworthy Wednesday Option Activity: TTNP, FCEL, PRLB

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Titan Pharmaceuticals Inc , where a total of 4,278 contracts have traded so far, representing approximately 427,800 underlying shares. That amounts to about 262.5% of TTNP's average daily trading volume over the past month of 163,000 shares.

Probuphine® (buprenorphine) Implant Phase 3 Data Presented At CPDD Annual Scientific Meeting

Probuphine® (buprenorphine) Implant Phase 3 Data Presented At CPDD Annual Scientific Meeting

Results Demonstrate the Superiority of Probuphine for Abstinence from Opioids for Patients over Six Months

Braeburn Pharmaceuticals Announces FDA Approves Probuphine® (buprenorphine) Implant: The First Implant For Treatment Of Opioid Dependence

Braeburn Pharmaceuticals Announces FDA Approves Probuphine® (buprenorphine) Implant: The First Implant For Treatment Of Opioid Dependence

Patients and Providers Have a New Option to Combat Opioid Dependence

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks trading for less than $10 a share look ready to break out and trade higher from current levels.

Titan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approval

Titan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approval

Titan Pharmaceuticals (TTNP) stock is climbing after the FDA's Psychopharmacologic Drugs Advisory Committee voted in favor of approving the company's treatment for opioid addiction.

4 Biotech Stocks Under $10 to Trade for Big Breakouts

4 Biotech Stocks Under $10 to Trade for Big Breakouts

These under-$10 biotech stocks are within range of triggering major breakout trades.

Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle

Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle

Titan and its partner will resubmit Probuphine for FDA approval later this year.

TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Potential Breach Of Fiduciary Duty

TITAN PHARMACEUTICALS (TTNP) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Titan Pharmaceuticals, Inc. For Potential Breach Of Fiduciary Duty

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Titan Pharmaceuticals,...

FDA Rejection of Titan's Probuphine Looks Like a Mugging

FDA Rejection of Titan's Probuphine Looks Like a Mugging

FDA find much at fault with Titan's implantable therapy for opioid dependence.